M

    Marker Therapeutics Inc (MRKR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.33
    -0.04 (-2.92%)

    Market Cap: $22.18M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    63%(20/32)
    Avg Surprise
    -8.00%
    Streak
    4 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.14
    Range$-0.16 - $-0.12
    2 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.12+14.3%
    60d ago$-0.12+14.3%
    30d ago$-0.18-32.1%
    7d ago$-0.18-32.1%
    Current$-0.14
    Revenue Consensus
    $2M
    Range$700000 - $4M
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.06
    Range$-0.12 - $0.01
    2 analysts
    Revenue Consensus
    $762670
    Range$-679330 - $2M
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.06---
    Sep 26EST
    		-$-0.14---
    Jun 26
    Reported Aug 13
    		$-0.09N/A+64.00%Beat+69.0%
    Mar 26
    Reported May 15
    		$-0.16$-0.19+15.79%Beat+60.0%
    Dec 25
    Reported Mar 18
    		$-0.04N/A+78.95%Beat+90.5%
    Sep 25
    Reported Nov 13
    		$-0.12$-0.21+42.86%Beat+53.8%
    Jun 25
    Reported Aug 14
    		$-0.29$-0.27-7.41%Miss-16.0%
    Mar 25
    Reported May 21
    		$-0.40$-0.66+39.39%Beat-48.1%
    Dec 24
    Reported Mar 31
    		$-0.42$-0.22-90.91%Miss+12.5%
    Sep 24
    Reported Nov 14
    		$-0.26$-0.39+33.33%Beat+23.1%
    Jun 24
    Reported Aug 14
    		$-0.25$-0.43+41.86%Beat-187.4%
    Mar 24
    Reported May 15
    		$-0.27$-0.25-8.00%Miss+52.6%
    Dec 23
    Reported Mar 26
    		$-0.48N/A+52.00%Beat+85.3%
    Sep 23
    Reported Nov 9
    		$-0.34N/AN/ABeat+57.8%
    Jun 23
    Reported Aug 14
    		$0.29$0.00N/ABeat+126.0%
    Mar 23
    Reported May 16
    		$-0.57$-0.80+28.80%Beat+52.5%
    Dec 22
    Reported Mar 22
    		$-3.27$-1.00-227.00%Miss-197.3%
    Sep 22
    Reported Nov 10
    		$-0.80$-1.30+38.46%Beat+46.7%
    Jun 22
    Reported Aug 11
    		$-1.10$-1.03-6.80%Miss+15.4%
    Mar 22
    Reported May 13
    		$-1.20$-1.33+9.77%Beat+25.0%
    Dec 21
    Reported Mar 17
    		$-1.10$-1.27+13.39%Beat+38.9%
    Sep 21
    Reported Nov 10
    		$-1.50$-1.27-18.11%Miss+6.3%
    Jun 21
    Reported Aug 10
    		$-1.30$-1.17-11.11%Miss+7.1%
    Mar 21
    Reported May 12
    		$-1.60$-1.45-10.34%Miss-14.3%
    Dec 20
    Reported Mar 9
    		$-1.80$-1.60-12.50%Miss-63.6%
    Sep 20
    Reported Nov 9
    		$-1.60$-1.45-10.34%Miss-33.3%
    Jun 20
    Reported Aug 10
    		$-1.40$-1.43+2.10%Beat-16.7%
    Mar 20
    Reported May 11
    		$-1.40$-1.23-13.82%Miss-16.7%
    Dec 19
    Reported Mar 12
    		$-1.10$-1.26+12.70%Beat+89.2%
    Sep 19
    Reported Nov 12
    		$-1.20$-1.32+9.09%Beat+62.5%
    Jun 19
    Reported Aug 8
    		$-1.20$-1.27+5.51%Beat-192.7%
    Mar 19
    Reported May 9
    		$-1.20$-1.30+7.69%Beat-300.0%
    Dec 18
    Reported Mar 15
    		$-10.20$-2.03-402.46%Miss-240.0%
    Sep 18
    Reported Nov 13
    		$-3.20$-4.40+27.27%Beat-720.5%
    Jun 18
    Reported Aug 9
    		$-0.41$0.00N/ABeat-85.7%
    Mar 18
    Reported May 15
    		$-0.30$-0.30+0.00%Beat-4.5%
    Dec 17
    Reported Mar 23
    		$-3.00$-5.00+40.00%Beat-1502.6%
    Sep 17
    Reported Nov 14
    		$-0.39N/AN/ABeat-35.0%
    Jun 17
    Reported Aug 7
    		$-0.22N/AN/ABeat-
    Mar 17
    Reported May 5
    		$-0.29N/AN/ABeat-
    Dec 16
    Reported Mar 14
    		$-0.19N/AN/ABeat-
    Sep 16
    Reported Nov 4
    		$-0.29N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-3.24EV/EBITDA-0.22x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-245.50%Operating Margin-267.90%
    ROE-76.90%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio6.03xQuick Ratio6.03x
    Trading Statistics
    Beta1.51Avg Volume76.90K
    52-Week High$2.4652-Week Low$0.83

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.37
    SMA 20$1.26
    SMA 50$1.31
    SMA 200$1.43
    EMA 10$1.36
    EMA 20$1.31
    EMA 50$1.31
    EMA 200$1.37

    MACD

    Line: 0.04Signal: 0.02Hist: 0.02

    ADX

    ADX: 28.4+DI: 26.3-DI: 16.2

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down12.0
    PSAR$1.32

    Bollinger Bands

    Upper Band$1.54
    Lower Band$0.97
    %B Position4576%(Upper)
    Band Width0.63

    RSI (14-Day)

    Neutral
    51.9

    Momentum Oscillators

    Stoch %K58.4
    Stoch %D66.9
    Williams %R-52.9
    ROC (10d)14.7%
    Momentum0.17
    CCI (20d)48.7
    MFI (14d)71.6

    Volatility Measures

    ATR (14d)$0.11(7.9%)
    StdDev (20d)0.14
    Hist Vol90.0%(High)

    Volume Flow

    VWAP$1.35
    OBV18.1M
    AD Line-91.6M
    CMF (20d)-0.099

    Volume Metrics

    Avg Vol (20d)77.5K
    Vol Ratio0.8x
    VWMA (20d)$1.31

    Pivot Points

    R3$1.61
    R2$1.56
    R1$1.46
    Pivot Point$1.41
    S1$1.31
    S2$1.26
    S3$1.16

    Advanced Oscillators

    TSI11.78
    Ultimate Osc42.3
    KST57.40

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$1.10M$1.23M$0$0$2.25M$1.93M$1.17M$1.24M$1.06M$257,606
    Cost of Revenue$0$0N/A$0$0$0$5.09M$0$0$0$2.62M$0
    Gross Profit$0$0$1.10M$1.23M$0$0$2.25M$1.93M$1.17M$1.24M$1.06M$257,606
    Operating Expenses$2.62M$4.07M$2.99M$3.37M$5.12M$4.96M$6.11M$4.33M$3.48M$3.79M$3.99M$3.46M
    R&D$1.48M$2.84M$2.14M$2.35M$4.18M$3.14M$5.09M$3.47M$2.34M$2.58M$2.62M$2.04M
    SG&A$1.14M$1.23M$846,607$1.02M$945,163$1.37M$1.03M$854,677$1.14M$1.22M$1.38M$1.41M
    Operating Income$-2,620,366$-4,072,535$-1,883,994$-2,136,726$-5,122,217$-4,957,777$-3,861,417$-2,399,873$-2,308,065$-2,549,017$-2,937,793$-3,200,046
    Interest Income$112,558$132,889$165,628$138,064$128,025$162,489$73,746$91,681$115,388$156,195$201,339$218,085
    Interest Expense$0$0$4.16M$0$0$0$0$0$0$0$0$0
    Income Before Tax$-1,826,229$-3,187,955$-6,047,106$-1,998,662$-4,133,008$-4,446,184$-3,787,671$-2,308,192$-2,192,677$-2,392,822$-2,736,454$-2,981,961
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-1,826,229$-3,179,278$-1,703,210$-1,998,662$-4,015,564$-4,446,184$-3,837,624$-2,308,192$-2,192,677$-2,392,822$-2,803,066$-2,981,961
    EBITDA$-1,938,787$-3,320,844$-1,883,994$-2,136,726$-4,261,033$-4,608,673$-3,861,417$-2,399,873$-2,308,065$-2,549,017$-2,937,793$-3,200,046
    EBIT$-1,938,787$-3,320,844$-1,883,994$-2,136,726$-4,261,033$-4,608,673$-3,861,417$-2,399,873$-2,308,065$-2,549,017$-2,937,793$-3,200,046
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about MRKR

    News

    H.C. Wainwright reiterates Marker Therapeutics stock rating at buy By Investing.com

    H.C. Wainwright has reiterated a Buy rating and a $10.00 price target for Marker Therapeutics (NASDAQ:MRKR), noting significant upside potential from its current trading price of $1.22. The biotech firm, with a market cap of $20.17 million, is advancing its Cellipont Bioservices technology transfer and anticipates a pivotal lymphoma trial in 2026. Marker Therapeutics also received a $4.2 million grant for clinical investigation of MT-601 and is expected to receive FDA feedback on its Phase 2b design in the latter half of 2026.

    Investing.com Canada•8/21/26•
    Bullish

    Marker Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview

    Marker Therapeutics Inc is projected to report a loss of 22 cents per share. This information comes from an earnings preview. The full article content requires unlimited access to TradingView.

    TradingView•8/10/26•
    Somewhat-Bearish

    Marker Therapeutics Inc (MRKR) Earnings Forecast: Future EPS & Revenue Growth Estimates

    Marker Therapeutics Inc (MRKR) has an earnings forecast score of 8.00, ranking 171st in the Biotechnology & Medical Research industry. Analysts have set an average price target of $9.00 for MRKR, with expectations for its next quarter's revenue at $682.00K and EPS at -$0.22. Most analysts recommend a "Buy" trend for the stock.

    TradingKey•8/6/26•
    Bullish

    Marker Therapeutics Inc (MRKR) Institutional Confidence

    Marker Therapeutics Inc (MRKR) has an institutional shareholding score of 3.00, placing it 191st out of 384 in the Biotechnology & Medical Research industry. Institutional shareholding proportion increased by 17.09% quarter-over-quarter to 26.04%. James Simons is identified as the largest institutional shareholder, albeit with a slight decrease in holdings.

    TradingKey•7/30/26•
    Neutral

    Marker Therapeutics Inc (MRKR) Risk Assessment: Volatility, Financial Risk & Investment Risk

    This article provides a risk assessment for Marker Therapeutics Inc (MRKR), highlighting its current risk score and beta value. It details the company's performance metrics, including volatility, maximum drawdown, and daily returns over various periods. The assessment also includes liquidity measures like turnover rate and deviation.

    TradingKey•7/30/26•
    Neutral

    Frequently Asked Questions About MRKR

    Does MRKR pay dividends?
    Marker Therapeutics Inc (MRKR) does not currently pay a regular dividend.
    What is MRKR's market cap?
    Marker Therapeutics Inc (MRKR) has a market capitalization of $22.18M with a current stock price of $1.33.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In